Last reviewed · How we verify
Atopic Dermatitis
Approved treatments
- Flucorticin
- Aclovate
- In open-label phase: treatment with tofacitinib · Pfizer
- Solu-Cortef · Pfizer
- Cordran · Aqua Pharms
- Corectim · Japan Tobacco
Delgocitinib works by blocking the JAK2 enzyme, which plays a key role in the immune system's inflammatory response. - Cutivate · Teva Pharm
- Temovate · Fougera Pharms
- Olumiant · Eli Lilly
- Cortifoam · Pfizer
- Benzamycin · Mayne Pharma
- Topicort · Taro
- Hydroxyzine Hydrochloride · Pfizer
- Derma-Smoothe/Fs · Eurofarma
- Cloderm · Legacy Pharma
- Prograf · Astellas Pharma
Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell. - Cortone
- Ultravate · Ranbaxy
Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation. - Diprolene · Merck & Co.
Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system. - Dupixent · Regeneron
Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response. - Verdeso · Padagis Us
- Betamethasone Valerate · Fougera Pharms Inc
- Celestone Soluspan
- Decadron · Generic (originally Merck)
- Flonase · GSK (GlaxoSmithKline)
- Eucrisa · Anacor Pharms Inc
Crisaborole inhibits phosphodiesterase 4, increasing intracellular cAMP levels for atopic dermatitis treatment. - Flixotide · Mundipharma Research Limited
- prednison · Wen Zhang
- Olumiant · NHS Greater Glasgow and Clyde
- Nasonex · University of Alberta
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Betamethasone 17-Benzoate
- Cortef · Generic (originally Merck/Upjohn)
- Rodinolone
- Fluticason · Creighton University
- Deltasone · Generic (originally Schering)
- Moizerto · OTSUKA PHARMACEUTICAL Co., Ltd
- Cibinqo · Pfizer
Cibinqo works by blocking the activity of the JAK1 enzyme, which plays a key role in the inflammatory response. - Elidel · Bausch Health
Elidel works by inhibiting calcineurin, a protein that helps activate T-cells, which are involved in the allergic response. - Lidex
- Eucrisa · Anacor Pharms Inc
Eucrisa works by blocking the phosphodiesterase 4 enzyme, which helps reduce inflammation in the skin. - Halog · Sun Pharma
- Lac-Hydrin · Sun Pharma
- Zonalon
Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood. - Dermatop · Bausch Health
- Depo-Medrol · Pfizer
Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response. - Eumovate
- Elocon · Merck & Co.
Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body. - Psorcon · Pfizer
- Cibinqo · Pfizer
Cibinqo works by blocking the JAK1 enzyme, which helps reduce inflammation in the body.
Pipeline
- PF-07038124 · Pfizer Inc. — Phase 2
Clinical guidelines
- FDA label — 1L
EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. - FDA label — 2L
CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. - FDA label — 2L
CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: